Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Biotechnology

Healthcare
$1.03 +6.12%

+$0.06 today

Market cap
$50.06M
Beta
0.29
P/E (TTM)
-1.4
EPS (TTM)
-$0.71
52W Low $0.27High $1.83

Volume 1.85M

Average 5.09M

HOWL Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Werewolf Therapeutics, Inc.NASDAQ: HOWL

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares growth accelerates

Q2 FY2026 weighted avg shares of 48.6M shares rose 8.0% year over year, ahead of the +6.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +16.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +8.0% holds above the trailing-twelve-month pace of +6.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
48.6M+0.0% QoQ
Last fiscal yearDec 2025
46.02M+6.2% YoY
LTMJun 2026
47.17M+6.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.0%——
1 year+6.2%——
3-year CAGR+16.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
46.02M USD
Year-over-year change
+6.2%
4-year CAGR
+25.7%

Weighted Avg Shares vs competitors

How HOWL compares with its peers on the latest reported figures

  • HOWL's LTM Jun 2026 weighted avg shares of 47.17M shares is the 2nd highest of the 8 companies compared; the peer median is 25.76M shares.
  • Its year-over-year change of +6.0% is the 7th highest of 8, against a peer median of +51.8%.
  • Over three fiscal years its annual growth of +16.8% compares with a peer median of +14.0%.
HOWL Competitors Peer median
Weighted Avg Shares for HOWL and competitors
Company Period LTM YoY 3-year CAGR
OTLKOutlook Therapeutics, Inc.LTM Mar 202653.45M +120.6%+48.6%
HOWLWerewolf Therapeutics, Inc.LTM Jun 202647.17M +6.0%+16.8%
OSTXOS Therapies IncorporatedLTM Mar 202631.25M -31.1%+8.2%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202626.06M +115.3%-31.2%
INMBINmune Bio, Inc.LTM Mar 202625.76M +22.3%+14.0%
ACETAdicet Bio, Inc.LTM Mar 20267.26M +28.8%+39.0%
CUECue Biopharma, Inc.LTM Mar 20263.74M +79.5%+38.5%
SPRBSpruce Biosciences, Inc.LTM Mar 2026827.01K +51.8%+7.8%
Peer median (excluding HOWL) 25.76M+51.8%+14.0%

Competitors are the stored peer set for HOWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue016.4M19.94M1.89M0
Cost of Revenue02.51M1.76M1.81M1.63M
Gross Profit013.89M18.18M71K(1.63M)
Gross Margin—84.7%91.2%3.8%—
Research & Development35.27M53.76M41.78M56.43M44.83M
Selling, General & Admin14.82M21.5M18.67M19.05M15.85M
Operating Expenses50.09M69.95M58.68M73.67M59.04M
Depreciation & Amortization216K1.1M1.76M1.81M1.63M
EBITDA(49.77M)(52.71M)(32.47M)(64.05M)(53.91M)
EBITDA Margin—-321.4%-162.8%-3397.6%—
Operating Income(50.09M)(56.06M)(40.5M)(73.59M)(60.68M)
Operating Margin—-341.8%-203.1%-3904.2%—
Interest Income104K1.91M7.42M6.67M3.11M
Interest Expense003.14M4.66M5.27M
Other Income / Expenses104K2.25M3.14M3.08M(145K)
Income Before Tax(49.98M)(53.81M)(37.37M)(70.52M)(60.82M)
Pre-Tax Margin—-328.1%-187.4%-3740.8%—
Income Tax Expense00000
Net Income(49.98M)(53.81M)(37.37M)(70.52M)(60.82M)
Net Margin—-328.1%-187.4%-3740.8%—
EPS (Basic)(10.94)(1.86)(1.05)(1.63)(1.32)
EPS (Diluted)(10.94)(1.86)(1.05)(1.63)(1.33)
Weighted Avg Shares18.46M28.86M35.65M43.33M46.02M
Weighted Avg Shares (Diluted)18.46M28.86M35.65M43.86M46.81M

Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.